drugset
drugset / Trial / NCT06372223

A Food Effect Study of SPH5030 Tablets.

NCT06372223 ↗

Phase 1 Completed 16 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy Chinese adult subjects.

Timeline

Start
2024-03-04
Primary completion
2024-03-25
Completion
2024-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject SPH5030 Small molecule 400 mg Oral

Indications

neoplasm